Regeneron Pharmaceuticals, Inc.
Jason Pitofsky (SVP Controller) sells REGN shares
AI-generated summary
SVP Controller Jason Pitofsky exercised options to acquire 3,883 shares of Common Stock for a total value of $2,487,685.12. He also sold 4,062 shares of Common Stock in open-market transactions for a total value of $3,827,159.46 at an average price of $942.19. Following these transactions, he holds 0 shares indirectly by spouse.
Key facts
- Insider
- Jason Pitofsky · SVP Controller
| Date | Transaction | Shares | Price | Value | Held after | Ownership |
|---|---|---|---|---|---|---|
| Nov 4, 2026 | M · exercise or conversion of a derivative | +1,500 | $726.53 | $1,089,795.00 | 5,772 | Direct |
| Nov 4, 2026 | M · exercise or conversion of a derivative | +1,478 | $644.54 | $952,630.12 | 7,250 | Direct |
| Nov 4, 2026 | M · exercise or conversion of a derivative | +905 | $492.00 | $445,260.00 | 8,155 | Direct |
| Nov 4, 2026 | S · open-market saleFootnotes F1 | −439 | $939.57 | $412,471.23 | 7,716 | Direct |
| Nov 4, 2026 | S · open-market saleFootnotes F2 | −575 | $940.46 | $540,764.50 | 7,141 | Direct |
| Nov 4, 2026 | S · open-market saleFootnotes F3 | −982 | $941.58 | $924,631.56 | 6,159 | Direct |
| Nov 4, 2026 | S · open-market saleFootnotes F4 | −1,215 | $942.31 | $1,144,906.65 | 4,944 | Direct |
| Nov 4, 2026 | S · open-market saleFootnotes F5 | −529 | $943.53 | $499,127.37 | 4,415 | Direct |
| Nov 4, 2026 | S · open-market saleFootnotes F6 | −108 | $944.22 | $101,975.76 | 4,307 | Direct |
| Nov 4, 2026 | S · open-market sale | −35 | $945.61 | $33,096.35 | 4,272 | Direct |
| Nov 4, 2026 | S · open-market saleFootnotes F7 | −179 | $950.76 | $170,186.04 | 0 | Indirect (by Spouse) |
| Nov 4, 2026 | M · exercise or conversion of a derivativeNon-Qualified Stock Option (right to buy)Footnotes F8 | −905 | $0.00 | $0.00 | 0 | Direct |
| Nov 4, 2026 | M · exercise or conversion of a derivativeNon-Qualified Stock Option (right to buy)Footnotes F8 | −1,478 | $0.00 | $0.00 | 500 | Direct |
| Nov 4, 2026 | M · exercise or conversion of a derivativeNon-Qualified Stock Option (right to buy)Footnotes F8 | −1,500 | $0.00 | $0.00 | 2,478 | Direct |
Footnotes
- F1 Represents volume-weighted average price of sales of 439 shares of Company stock on November 4, 2026 at prices ranging from $939.10 to $939.71. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 4, 2026 at each separate price.
- F2 Represents volume-weighted average price of sales of 575 shares of Company stock on November 4, 2026 at prices ranging from $940.15 to $940.88. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 4, 2026 at each separate price.
- F3 Represents volume-weighted average price of sales of 982 shares of Company stock on November 4, 2026 at prices ranging from $941.08 to $941.92. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 4, 2026 at each separate price.
- F4 Represents volume-weighted average price of sales of 1,215 shares of Company stock on November 4, 2026 at prices ranging from $942.00 to $942.92. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 4, 2026 at each separate price.
- F5 Represents volume-weighted average price of sales of 529 shares of Company stock on November 4, 2026 at prices ranging from $943.00 to $943.88. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 4, 2026 at each separate price.
- F6 Represents volume-weighted average price of sales of 108 shares of Company stock on November 4, 2026 at prices ranging from $944.00 to $944.34. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 4, 2026 at each separate price.
- F7 Represents volume-weighted average price of sales of 179 shares of Company stock on November 4, 2026 at prices ranging from $950.45 to $950.78. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 4, 2026 at each separate price.
- F8 The stock option award vested in four equal annual installments, commencing one year after the date of grant.
More REGN filings
- 4
Filed Nov 5, 2026
- 13F-HR
Filed Nov 5, 2026
- 4
Filed Nov 5, 2026
- 144
Filed Nov 4, 2026
- 4
Filed Nov 4, 2026
- 4
Filed Nov 4, 2026
Not investment advice. Summaries can contain errors; the SEC filing is the official record.